CNS Pharmaceuticals, Inc. Common Stock

CNS Pharmaceuticals, a biopharmaceutical company, is developing novel treatments for brain and central nervous system cancers. The company's lead drug candidate, Berubicin, is in a late-stage pivotal trial, and it has recently in-licensed another promising drug, TPI-287, for glioblastoma treatment.

Related tickers: CNSP.

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below 30, according to Benzinga Pro. Here’s the latest list of major oversold players in this sector, having an RSI near or below 30. BIOLASE, Inc. (NASDAQ: BIOL) On Jan. 29, Biolase reported full-year 2023 interim revenue of $48.9 million to $49.2 million, up 1% year-over-year compared to the consensus of $49.21 million. The company’s stock fell around 43% over the past five days ...

Related tickers: GILD, BIOL, ZLAB, REVB, CNSP.